Bayer's Stivarga – doomed to be an also-ran?
This article was originally published in Scrip
Executive Summary
Bayer HealthCare has halted a Phase III study of its oral multi-kinase inhibitor Stivarga (regorafenib) investigating its use as an adjuvant in patients with colorectal cancer who have undergone resection of liver metastases because it cannot get enough patients to enrol.